Search Results for “EC” – Page 253 – media

Abbott Earns FDA Approval For Dissolving Stent That Unclogs Arteries Below The Knee

Abbott earned a groundbreaking FDA approval on Monday for its dissolving stent designed to unclog arteries below the knee. The device, called the Esprit BTK System, is meant to treat patients who have chronic limb-threatening ischemia below the knee. This condition is characterized by insufficient blood flow to the lower extremities, which leads to persistent pain, ulcers and tissue necrosis — with a significant risk of limb amputation if left untreated Chronic limb-threatening ischemia below the knee may be the most severe form of peripheral artery disease, said Jennifer Jones-McMeans, divisional vice president of global clinical affairs at Abbott’s vascular business. “This is really a landmark moment,” she said in an interview. “We’re looking at the first dissolving stent to treat below-the-knee arterial disease. And really, when you look at this severe form of upper artery disease, it’s considered kind of the terminal end of this disease — meaning that these patients have ...
- Source: drugdu
- 106
- May 5, 2024
UK sets out position on regulating AI as a medical device

Dive Brief A U.K. agency outlined its position on the regulation of artificial intelligence as a medical device in a policy paper published Tuesday.The Medicines and Healthcare products Regulatory Agency (MHRA) said many AI products that can be put on the market now without conformity assessment will move to a higher risk category in upcoming reforms.The paper explains how MHRA interprets a government AI strategy focused on principles such as safety, security and robustness and aligns it with international standards. Dive Insight The U.K. government committed to five cross-sector principles for the regulation of AI in February. A consultation found “strong support” for the principles, the government said, and established them as the basis for a regulatory framework designed to keep pace with rapidly advancing AI technology. Days later, the government wrote to the MHRA to request details of its approach to AI. In response, the MHRA published a policy ...
- Source: drugdu
- 109
- May 5, 2024
Patient Rights Advocate Files Amicus Brief in Lawsuit Against Blue Cross Blue Shield of Minnesota

The fight over affordable drug prices continues. PatientRightsAdvocate.org announced that it has filed an amicus brief in the Department of Labor’s (DOL) case against Blue Cross Blue Shield of Minnesota.1 Acting secretary of labor Julie A. Su filed the case in January of this year, claiming that Blue Cross collected about $66.8 million for provider taxes from 370 self-funded employer health plans. Provider taxes vary from state to state, but they are typically paid by hospitals and clinics. These funds can be used as a source of funding for Medicaid, provided they meet certain requirements. In the lawsuit,2 the DOL of writes, “BCBSM, Inc. has for years unilaterally caused the self-funded health benefit plans for which it serves as third-party administrator to compensate BCBSM, Inc.’s in-network providers for amounts they owe under a Minnesota provider tax—amounts the providers never billed or passed on to the plans—without authority to do so under the ...
- Source: drugdu
- 110
- May 5, 2024
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data

Gilead Sciences has received a US Food and Drug Administration (FDA) approval for the label expansion of its human immunodeficiency virus -1 (HIV-1) fixed dose combination therapy, Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg). The therapy is approved in pregnant patients in their second and third trimesters and up to 16 weeks following delivery (postpartum) with suppressed viral loads of HIV-1. The FDA first approved Biktarvy as a complete regimen for treating HIV-1 in adults who either have no antiretroviral treatment history or as a replacement for the current antiretroviral regimen in those who are virologically suppressed, in 2018.The FDA label expansion was based on the data from an open-label Phase Ib trial (study 5310). The single-arm study evaluated the pharmacokinetics, safety, and efficacy of Biktarvy in 32 pregnant patients with suppressed viral loads of HIV-1. All the participants maintained viral suppression during pregnancy and through 18 weeks postpartum, with lower ...
- Source: drugdu
- 76
- May 5, 2024
Sino Biological concludes SignalChem acquisition for $48m.

Sino Biological has concluded the acquisition of Canadian biotechnology company SignalChem Biotech (SCB) for $48m in a move that expands its product portfolio and strengthens its global presence. The related share purchase agreement was signed between the companies in October 2023. The deal includes all assets and assumed indebtedness, along with net cash deposits, marking a significant expansion for the Shenzhen stock exchange-listed biotech company. Sino Biological president and general manager Dr Jie Zhang stated: “SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. “The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services.” SignalChem is engaged in developing bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. It is now integrated as a wholly-owned subsidiary of Sino Biological. SCB will offer exclusive ...
- Source: https://www.pharmaceutical-technology.com/news/sino-biological-signalchem-48m/
- 77
- May 4, 2024
“Profound concern” over WHO’s pandemic agreement, says AIDS charity

The AHF Global Public Health Institute has voiced concerns over the World Health Organization’s (WHO) proposed pandemic agreement, saying that the private interest of pharmaceutical companies has taken priority over global health security. The AHF Global Public Health Institute, a joint initiative of the AIDS Healthcare Foundation and the University of Miami, outlined issues in the latest iteration of the text from the WHO via a 26 April press release. The Pandemic Agreement, also known as the pandemic accord, is a proposed international joint initiative to fight the next pathogen that threatens global health. The framework is meant to implement lessons learned from the response to Covid-19 to improve shared response between nations. Member states have a deadline of May 2024 to join the treaty accord. Research indicates that Covid-19 would have caused 40 million more deaths in the absence of preventative measures. Countries have been ...
- Source: https://www.pharmaceutical-technology.com/news/profound-concern-over-whos-pandemic-agreement-says-aids-charity/?cf-view
- 128
- May 4, 2024
ClearPoint Neuro wins FDA clearance for neuro laser therapy accessory

BY SEAN WHOOLEY The ClearPoint Prism neuro laser therapy system. [Image courtesy of ClearPoint Neuro] ClearPoint Neuro (Nasdaq:CLPT) announced today that the FDA granted 510(k) clearance for its Prism bone anchor accessory. It marks the second new product introduction in 2024 for the company, with its stereotactic guidance system garnering clearance in January. The Prism system features the only non-cooled laser applicator on the market, the company said. Its next-generation laser applicator technology eliminates the need for external cooling. This simplifies setup, reduces power and ablation time and lessens imaging artifact for more efficient workflows. ClearPoint Neuro designed its Prism bone anchor accessory for use with commercially available stereotactic systems. These systems work for intracranial and neurosurgical procedures. Such procedures require accurate positioning of compatible small surgical instruments or accessories in the cranium, brain or nervous systems. The anchor provides short-term fixation and positioning of those instruments or accessories under image guidance. Chris Osswald, director, ...
- Source: https://www.massdevice.com/author/sean-whooley/
- 94
- May 4, 2024
FDA Approves Aquestive Therapeutics’ Libervant for the Treatment of Seizure Clusters in Children Aged 2 to 5 Years

Don Tracy, Associate Editor Approval of Libervant marks the first orally administered rescue medication for this age group to be cleared by the FDA for epilepsy. Image Credit: Adobe Stock Images/Justlight Aquestive Therapeutics announced that the FDA has officially approved Libervant (diazepam) Buccal Film to treat seizure clusters in children aged two to five years. According to the company, the film works by being applied inside the cheek, where it naturally dissolves and provides a steady dose of diazepam. Currently, most prescriptions are being prepared, with Medicaid expected to be added at a later date. Libervant is the first and only FDA-approved orally administered rescue medication for seizures in this age group.1 “We are thrilled to have received FDA approval for Libervant in patients between the ages of two and five,” said Daniel Barber, CEO, Aquestive, in a press release. “Patients have been waiting years for Libervant, the first and ...
- Source: https://www.pharmexec.com/authors/don-tracy-associate-editor
- 97
- May 4, 2024
Urine Test to Revolutionize Lyme Disease Testing

Lyme disease is the most common animal-to-human transmitted disease in the United States, with around 476,000 people diagnosed and treated annually, and its incidence has been increasing. If not addressed promptly and effectively, those affected may experience persistent symptoms known as Post-Treatment Lyme Disease Syndrome, which include issues with concentration and memory, dizziness, fatigue, body aches, depression, and sleep disturbances. Currently, the standard diagnostic approach involves an antibody blood test that detects the immune system’s response to the bacteria responsible for Lyme disease. Now, urine testing could revolutionize Lyme disease detection and diagnosis thanks to its many advantages over existing techniques. Researchers at George Mason University (Fairfax, VA, USA) have developed a urine test for Lyme disease that detects the Borrelia bacteria, which causes Lyme disease. This advancement allows for the confirmation of an infection shortly after a tick bite, leading to timely treatment and helping to avoid the ...
- Source: https://www.labmedica.com/molecular-diagnostics/articles/294801060/urine-test-to-revolutionize-lyme-disease-testing.html
- 96
- May 4, 2024
FDA Approves New Herceptin Biosimilar for the Treatment of Multiple HER2-Overexpressing Cancers

Don Tracy, Associate Editor Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for HER2-overexpressing breast and gastric cancers. Image Credit: Adobe Stock Images/Saiful52 Accord BioPharma announced that the FDA has approved Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast and gastric cancers. The treatment is also approved for metastatic gastric or gastroesophageal junction adenocarcinoma. According to the company, the approval was based on promising data that showcased Hercessi’s biosimilarity to Herceptin when it came to efficacy, safety, and quality. This includes three studies, one being a Phase III clinical efficacy study, and the other two being Phase 1 PK equivalence studies. All trials displayed safety profiles on par with Herceptin.1 “The approval of Hercessi—our first biosimilar to be approved in the US—marks an important milestone for Accord BioPharma in our efforts ...
- Source: https://www.pharmexec.com/authors/don-tracy-associate-editor
- 89
- May 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.